Brainstorm Cell Therapeutics BCLI
OTC BCLI
$0.77 -0.02 (-2.53%)
As of: Oct 21, 2026 · 11:49 AM EDT

Brainstorm Cell Therapeutics (BCLI) Non-Current Deffered Revenue (2017 - 2019)

Updated

Brainstorm Cell Therapeutics (BCLI) recorded Non-Current Deffered Revenue of $511,000 in Q1 2019, down 57.5% from $1.2 million a year earlier.

Analysis

Brainstorm Cell Therapeutics (BCLI) Non-Current Deffered Revenue (2017 - 2019) Analysis & Trends

At the end of FY2017, Brainstorm Cell Therapeutics reported Non-Current Deffered Revenue of $2.63 million.

  • Quarterly Non-Current Deffered Revenue has ranged from $130,000 in Q3 2018 to $5.25 million in Q3 2017 over the past five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Eli Lilly 1,171.37 Bn 1,139.96 Bn 19.71 Bn -
2 Johnson & Johnson 645.23 Bn 565.09 Bn 17.30 Bn -
3 AbbVie 502.25 Bn 475.37 Bn 12.70 Bn -
4 Merck 361.34 Bn 315.71 Bn 12.21 Bn -
5 Novartis Ag 302.82 Bn 266.81 Bn 11.24 Bn -
6 Astrazeneca 267.91 Bn 241.60 Bn 12.86 Bn -
7 Amgen 242.39 Bn 197.79 Bn 7.24 Bn -
8 Gilead Sciences 193.55 Bn 167.74 Bn 6.22 Bn -
9 Pfizer 172.05 Bn 118.70 Bn 10.94 Bn -
10 Brainstorm Cell Therapeutics 8.50 Mn 8.43 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2019 511,000.00
Sep 30, 2018 130,000.00
Jun 30, 2018 1.89 Mn
Mar 31, 2018 1.20 Mn
Dec 31, 2017 2.63 Mn
Sep 30, 2017 5.25 Mn
API Access

Brainstorm Cell Therapeutics Non-Current Deffered Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=BCLI&period=max&api_key=YOUR_API_KEY